Enzo Biochem (FRA:EZB) Total Liabilities : €25.98 Mil (As of Jan. 2024)

View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem Total Liabilities?

Enzo Biochem's Total Liabilities for the quarter that ended in Jan. 2024 was €25.98 Mil.

Enzo Biochem's quarterly Total Liabilities declined from Jul. 2023 (€39.25 Mil) to Oct. 2023 (€30.34 Mil) and declined from Oct. 2023 (€30.34 Mil) to Jan. 2024 (€25.98 Mil).

Enzo Biochem's annual Total Liabilities declined from Jul. 2021 (€38.16 Mil) to Jul. 2022 (€20.79 Mil) but then increased from Jul. 2022 (€20.79 Mil) to Jul. 2023 (€39.25 Mil).

Enzo Biochem Total Liabilities Historical Data

The historical data trend for Enzo Biochem's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzo Biochem Total Liabilities Chart

Enzo Biochem Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Total Liabilities

Get a 7-Day Free Trial

18.39

47.12

38.16

20.79

39.25

Enzo Biochem Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Total Liabilities	Get a 7-Day Free Trial															40.48	48.46	39.25	30.34	25.98

Enzo Biochem Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Enzo Biochem's Total Liabilities for the fiscal year that ended in Jul. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	36.15	+	(3.1	+	1.3322676295502E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	39.25

Total Liabilities	=	Total Assets (A: Jul. 2023 )	-	Total Equity (A: Jul. 2023 )
	=	110.18	-	70.93
	=	39.25

Enzo Biochem's Total Liabilities for the quarter that ended in Jan. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	23.21	+	(2.771	+	8.8817841970013E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	25.98

Total Liabilities	=	Total Assets (Q: Jan. 2024 )	-	Total Equity (Q: Jan. 2024 )
	=	90.953	-	64.971
	=	25.98

Enzo Biochem Total Liabilities Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzo Biochem (FRA:EZB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (FRA:EZB) » Definitions » Total Liabilities

Comparable Companies

NOTV VNRX BIOQ STIM PSNL PRE OCX MDXH TTOO XGN TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN

Traded in Other Exchanges

ENZ:USA

Address

527 Madison Avenue, New York, NY, USA, 10022

Website

https://www.enzo.com

Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.

Enzo Biochem (FRA:EZB) Headlines

No Headlines